Recruiting

Predictive Signature of Benralizumab Response

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(20 sites)

France

Centre hospitalier Intercommunal Aix-en-Provence, Aix-en-Provence

CHU Angers, Angers

CHU Bordeaux, Bordeaux

CHRU Brest, Brest

CHU Dijon, Dijon

CHU Grenoble, Grenoble

Hôpital Bicêtre - AP-HP, Le Kremlin-Bicêtre

CH Mans, Le Mans

CHU Lille, Lille

Hospices Civils de Lyon, Lyon

Assistance Publique des Hôpitaux de Marseille, Marseille

CHU Montpellier, Montpellier

CHU Nantes, Nantes

CHR Orléans, Orléans

Hôpital Bichat - AP-HP, Paris

CHU Rouen, Rouen

CHU Strasbourg, Strasbourg

Hôpital FOCH, Suresnes

CHU Toulouse, Toulouse

Médipôle Hôpital Mutualiste de Villeurbanne, Villeurbanne